fig4

New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer

Figure 4. Potential therapeutic targets for transformed SCLC from ALK-mutant NSCLC. These treatments include chemotherapy, ALK-TKIs, immunotherapy, radiation therapy, and CHK and PLK inhibitors targeting RB1 loss. Created in BioRender. Long, M. (2025). https://BioRender.com/gtgq662. SCLC: Small cell lung cancer; ALK: anaplastic lymphoma kinase; NSCLC: non-small cell lung cancer; TKIs: tyrosine kinase inhibitors; CHK: checkpoint kinase; PLK: polo-like kinase.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/